Topic: Carrie Cox
Schering-Plough Corporation (SGP) Q2 2009 Earnings Call July 21, 2009 7:45 am ET. This morning I'm joined by Fred Hassan, our Chairman and Chief Executive Officer, Bob Bertolini, our Chief Financial Officer, Carrie Cox, the head of Global Pharmaceuticals, and ...
Schering-Plough Corporation (SGP) Q4 2008 Earnings Call February 03, 2009 8:00 am ET. This morning, I am joined by Fred Hassan, our Chairman and Chief Executive Officer; Rob Bertolini, our Chief Financial Officer and Carrie Cox, the Head of our Global ...
Add a few U.S. attorneys to the long list of folks looking into what happened with that failed trial of Vytorin, the cholesterol drug from Merck and Schering-Plough.. In its quarterly report this week, Schering-Plough added the U.S. attorneys at ...
Schering Plough Corporation (SGP) Q3 FY08 Earnings Call October 21, 2008 8:00 am ET. This morning, I am joined by Fred Hassan, our Chairman and Chief Executive Officer; Bob Bertolini, our Chief Financial Officer; and Carrie Cox, the Head of Global ...
Schering Plough Corp. (SGP) Q2 FY08 Earnings Call July 22, 2008 4:45 pm ET. This afternoon, I am joined by Fred Hassan, our Chairman and Chief Executive Officer; Bob Bertolini, our Chief Financial Officer; and Carrie Cox, the Head of our ...
Add a few U.S. attorneys to the long list of folks looking into what happened with that failed trial of Vytorin, the cholesterol drug from Merck and Schering-Plough.. In its quarterly report this week, Schering-Plough added the U.S. attorneys at ...
How does Schering-Plough love Vytorin? "You can expect us to maintain broad support for Vytorin and Zetia. ". "The facts remain the same. Only Vytorin provides more than 50% LDL reduction at the usual starting dose and gets more patients to goal across ...
